Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis
| Autor: | Lyle L. Moldawer, Eric J. Sorscher, Nicki Koppersmith, Nancy Wooldridge, Jeanette Lee, Joy Atchison, J.P. Clancy, Ramin B. Arani, Valerie Eubanks, Christopher M. Makris, Raymond K. Lyrene |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Vital capacity Pancreatic disease Time Factors Adolescent Cystic Fibrosis Hydrocortisone Child Welfare Placebo Weight Gain Gastroenterology Pulmonary function testing FEV1/FVC ratio chemistry.chemical_compound Double-Blind Method Bone Density Internal medicine medicine Humans Insulin Child Lung Dose-Response Relationship Drug business.industry Megestrol Acetate Age Factors medicine.disease Surgery Treatment Outcome chemistry Megestrol acetate Megestrol Pediatrics Perinatology and Child Health Body Composition Female medicine.symptom business Weight gain medicine.drug |
| Zdroj: | The Journal of pediatrics. 140(4) |
| ISSN: | 0022-3476 |
| Popis: | Malnutrition is a negative prognostic indicator in patients with cystic fibrosis (CF) and may accentuate pulmonary decline. We tested whether megestrol acetate would have beneficial effects on growth in patients with CF and pancreatic insufficiency.We performed a randomized, double-blind, placebo controlled study. All patients were taking replacement enzymes to compensate for pancreatic insufficiency. Patients (n = 17) were randomly assigned to receive either megestrol acetate or placebo.The treatment group had a significant increase in weight-for-age z scores compared with placebo and reached 100% of their ideal body weight within 3 months of initiating therapy. Weight gain included both fat and fat-free mass. Improved pulmonary function (forced vital capacity and forced expiratory volume in 1 second) was noted in the treatment group compared with placebo (P.04). Reversible adrenal suppression was observed in the majority of patients who received megestrol acetate.Short-term use of megestrol acetate results in significant weight gain and improved pulmonary function in malnourished subjects with CF. Our study provides a controlled basis for this intervention, identifies important side effects, and provides the foundation for multiyear, longitudinal trials in a larger number of patients with CF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect